Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
about
Targeting T cells with bispecific antibodies for cancer therapyDevelopment and prospects for bispecific antibody-based therapeutics in cancer and other applications.Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
P2860
Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Unprimed CD4+ and CD8+ T cells ...... liferate and become cytotoxic.
@en
type
label
Unprimed CD4+ and CD8+ T cells ...... liferate and become cytotoxic.
@en
prefLabel
Unprimed CD4+ and CD8+ T cells ...... liferate and become cytotoxic.
@en
P2093
P356
P1476
Unprimed CD4+ and CD8+ T cells ...... liferate and become cytotoxic.
@en
P2093
A J Geerars
B C de Gast
I A Haagen
W B de Lau
P2888
P304
P356
10.1007/BF01534426
P577
1994-12-01T00:00:00Z
P6179
1029531940